Systemic chemotherapy in the treatment of malignant melanoma

Expert Opinion on Pharmacotherapy

Volumn 4, Issue 12, 2003, Pages 2205-2211

  Lens, Marko B ^a,b   Eisen, Tim G ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Chemotherapy; Melanoma; Metastatic

Indexed keywords

ALPHA INTERFERON; ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; BLEOMYCIN; BOLD PROTOCOL; BRYOSTATIN; CARBOPLATIN; CARMUSTINE; CISPLATIN; CVD PROTOCOL; CYCLOPHOSPHAMIDE; DACARBAZINE; DBPT REGIMEN; DOCETAXEL; FOTEMUSTINE; HYDROXYUREA; INTERLEUKIN 2; LOMUSTINE; PACLITAXEL; TAMOXIFEN; TEMOZOLOMIDE; VINBLASTINE; VINCRISTINE; VINCRISTINE SULFATE; VINDESINE;

ALOPECIA; ARTHRALGIA; BONE MARROW SUPPRESSION; CANCER SURVIVAL; CLINICAL TRIAL; COMPARATIVE STUDY; CONSTIPATION; DIARRHEA; DNA METHYLATION; DRUG ABSORPTION; DRUG CLEARANCE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG METABOLISM; DRUG RESPONSE; FATIGUE; FLU LIKE SYNDROME; FLUID RETENTION; HUMAN; LEUKOPENIA; LIVER METABOLISM; LIVER VENOOCCLUSIVE DISEASE; MELANOMA; METASTASIS; MONOTHERAPY; MORTALITY; MYALGIA; NAUSEA AND VOMITING; NEUROTOXICITY; NEUTROPENIA; PHOTOSENSITIVITY; REVIEW; SIDE EFFECT; SKIN TUMOR; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CARMUSTINE; CISPLATIN; CLINICAL TRIALS; CYCLOPHOSPHAMIDE; DACARBAZINE; HUMANS; LOMUSTINE; MELANOMA; NEOPLASM METASTASIS; SKIN NEOPLASMS; TAMOXIFEN; TREATMENT OUTCOME; VINCRISTINE;

EID: 0345735397     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.4.12.2205     Document Type: Review

References (50)

1. REINTGEN DS, RAPAPORT DP, TANABE KK, ROSS MI: Lymphatic mapping and sentinel lymphadenectomy. In: Cutaneous melanoma. (3rd edn). Balch CM, Houghton AN, Sober AJ, Soong S, (Eds), Quality Medical Publishing, St. Louis, MO, USA (1998):227-244.
2. AHMED I: Malignant melanoma: prognostic indicators. Mayo Clin. Proc. (1997) 72(4):356-361.
3. BUZAID AC, ANDERSON CM: The changing prognosis of melanoma. Curr. Oncol. Rep. (2000) 2(4):322-328.
4. ANDERSON CM, BUZAID AC, LEGHA SS: Systemic treatments for advanced cutaneous melanoma. Oncology (Huntingt) (1995) 9(11):1149-1158.
5. REID JM, KUFFEL MJ, MILLER JK, RIOS R, AMES MM: Metabolic activation of dacarbazine by human cytochromes P450: the role of CYP1A1, CYP1A2, and CYP2E1. Clin. Cancer Res. (1999) 5(8):2192-2197.
6. LEE SM, MARGISON GP, THATCHER N, O'CONNOR PJ, COOPER DP: Formation and loss of O6-methyldeoxyguanosine in human leucocyte DNA following sequential DTIC and fotemustine chemotherapy. Br. J. Cancer (1994) 69(5):853-857.
7. KLIMEK VM, WOLCHOK JD, CHAPMAN PB, HOUGHTON AN, HWU WJ: Systemic chemotherapy. Clin. Plast. Surg. (2000) 27(3):451-61.
8. BECKER JC, KAMPGEN E, BROCKER E: Classical chemotherapy for metastatic melanoma. Clin. Evp. Dermatol. (2000) 25(6):503-508.
9. NEWBY JC, EISEN T: The role of chemotherapy. In: Melanoma. Critical debates. Newton Bishop JA, Gore M (Eds), Blackwell Science, Oxford, UK (2002):178-194.
10. MARSH JC: Hepatic vascular toxicity of dacarbazine (DTIC): not a rare complication. Hepatolog (1989) 9(5):790-792.
11. CHAPMAN PB, EINHORN LH, MEYERS ML, SAXMAN S, DESTRO AN, PANAGEAS KS et al.: Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J. Clin. Oncol. (1999) 17(9):2745-2751.
12. LUIKART SD, KENNEALEY GT, KIRKWOOD JM: Randomized Phase III trial of vinblastine, bleomycin, and cisdichlorodiammine-platinum versus dacarbazine in malignant melanoma. J. Clin. Oncol. (1984) 2(3):164-168.
13. LOPEZ M, PERNO CF, DI LAURO L, PARALDO P, GANZINA F, BARDUAGNI A. Controlled study of DTIC versus DTIC plus epirubicin in metastatic malignant melanoma. Invest. New Drugs (1984) 2(3):319-322.
14. SUN W, SCHUCHTER LM: Metastatic melanoma. Curr. Treat. Options Oncol. (2001) 2(3):193-202.
15. DANSON SJ, MIDDLETON MR: Temozolomide: a novel oral alkylating agent. Expert Rev. Anticancer Ther. (2001) 1(1):13-19.
16. TENTORI L, GRAZIANI G: Pharmacological strategies to increase the antitumor activity of methylating agents. Curr. Med. Chem. (2002) 9(13):1285-1301.
17. BRITTEN CD, ROWINSKY EK, BAKER SD et al.: A Phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies. Clin. Cancer Res. (1999) 5(7):1629-1637.
18. YUNG WK: Future directions for temozolomide therapy. Semin. Oncol. (2001) 28(4 Suppl. 13):43-6.
19. AGARWALA SS, KIRKWOOD JM: Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma. Oncologist (2000) 5(2):144-151.
20. DOUGLAS JG, MARGOLIN K: The treatment of brain metastases from malignant melanoma. Semin. Oncol. (2002) 29(5):518-524.
21. NEWLANDS ES, BLACKLEDGE GR, SLACK JA et al.: Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). Br. J. Cancer (1992) 65:287-291.
22. BLEEHEN NM, NEWLANDS ES, LEE SM et al.: Cancer Research Campaign Phase II trial of temozolomide in metastatic melanoma. J. Clin. Oncol. (1995) 13:910-913.
23. MIDDLETON M, GROB J, AARONSON N et al.: Randomized Phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J. Clin. Oncol. (2000) 18:158-166.
24. KHAYAT D, GIROUX B, BERILLE J et al.: Fotemustine in the treatment of brain primary tumors and metastases. Cancer Invest. (1994) 12(4):414-420.
25. KLEEBERG UR, ENGEL E, ISRAELS P et al.: Palliative therapy of melanoma patients with fotemustine. Inverse relationship between tumour load and treatment effectiveness. A multicentre Phase II trial of the EORTC-Melanoma Cooperative Group (MCG). Melanoma Res. (1995) 5(3):195-200.
26. JACQUILLAT C, KHAYAT D, BANZET P et al.: Final report of the French multicenter Phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases. Cancer (1990) 66(9):1873-1878.
27. KHAYAT D, COUR V, BIZZARI JP et al.: Fotemustine (S 10036) in the intra-arterial treatment of liver metastasis from malignant melanoma. A Phase II Study. Am. J. Clin. Oncol. (1991) 14(5):400-404.
28. LEYVRAZ S, BOSSHARD W, SALMON R et al.: Prolonged survival of patients with liver metastases from ocular melanoma: multicentric experience with fotemustine hepatic arterial infusion. Proc. Am. Soc. Clin. Oncol. (2002) (Abstract 1360).
29. AAMDAL S, AVRIL MF, GROB JJ et al.: A Phase III randomized trial of fotemustine (F) versus dacarbazine (DTIC) in patients with disseminated malignant melanoma with or without brain metastases. Proc. Am. Sec. Clin. Oncol. (2002) (Abstract 1361).
30. LOPES NM, MILLER HP, YOUNG ND, BHUYAN BK: Assessment of microtubule stabilizers by semiautomated in vitro microtubule protein polymerization and mitotic block assays. Cancer Chemother. Pharmacol. (1997) 41(1):37-47.
31. BEDIKIAN AY, WEISS GR, LEGHA SS et al.: Phase II trial of docetaxel in patients with advanced cutaneous malignant melanoma previously untreated with chemotherapy. J. Clin. Oncol. (1995) 13(12):2895-2899.
32. AAMDAL S, WOLFF I, KAPLAN S et al.: Docetaxel (Taxotere) in advanced malignant melanoma: a Phase II study of the EORTC Early Clinical Trials Group. Eur. J. Cancer (1994) 30A(8):1061-1064.
33. BEDIKIAN AY, PAPADOPOULOS N, PLAGER C, ETON O, ELLERHORST J, SMITH T: Phase II evaluation of short IV infusion of paclitaxel in metastatic melanoma (M). Proc. Am. Soc. Clin. Oncol. (2002) (Abstract 1392).
34. STEFFENS TA, BAJORIN DF, CHAPMAN PB et al.: A Phase II trial of high-dose cisplatin and dacarbazine. Lack of efficacy of high-dose, cisplatin-based therapy for metastatic melanoma. Cancer (1991) 68(6):1230-1237.
35. TOZER RG, BURDETTE-RADOUX S, BERLANGER K et al.: A randomized Phase II study of two schedules of bryostatin-1 (NSC339555) in patients with advanced malignant melanoma: a National Cancer Institute of Canada Clinical Trials Group study. Invest. New Drugs (2002) 20(4):407-412.
36. GONZALEZ R, EBBINGHAUS S, HENTHORN TK, MILLER D, KRAFT AS: Treatment of patients with metastatic melanoma with bryostatin-1-a Phase II study. Melanoma Res. (1999) 9(6):599-606.
37. DEL PRETE SA, MAURER LH, O'DONNELL J, FORCIER RJ, LEMARBRE P: Combination chemotherapy with cisplatin, carmustine, dacarbazine, and tamoxifen in metastatic melanoma. Cancer Treat. Rep. (1984) 68(11):1403-1405.
38. SERRONE L, ZEULI M, SEGA FM, COGNETTI F: Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview. J. Exp. Clin. Cancer Res. (2000) 19(1):21-34.
39. LEGHA SS, RING S, PAPADOPOULOS N, PLAGER C, CHAWLA S, BENJAMIN R: A prospective evaluation of a triple-drug regimen containing cisplatin, vinblastine, and dacarbazine (CVD) for metastatic melanoma. Cancer (1989) 64(10):2024-2029.
40. BUZAID AC, LEGHA SS, WINN R et al.: Cisplatin (C), vinblastine (V), dacarbazine (D) (CVD) versus dacarbazine alone in metastatic melanoma: Preliminary results of a Phase III Cancer Community Oncology Program (CCOP). Proc. Ann. Meet. Am. Soc. Clin. Oncol. (1993) 12:1328.
41. ETON O, LEGHA SS, BEDIKIAN AY et al.: Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a Phase III randomized trial. J. Clin. Oncol. (2002) 20(8):2045-2052.
42. ATZPODIEN J, NEUBER K, KAMANABROU D et al.: Combination chemotherapy with or without s.c. IL-2 and IFN-alpha: results of a prospectively randomized trial of the Cooperative Advanced Malignant Melanoma Chemoimmunotherapy Group (ACIMM). Br. J. Cancer (2002) 86(2):179-184.
43. SEIGLER HF, LUCAS VERSUS JR, PICKETT NJ, HUANG AT: DTIC, CCNU, bleomycin and vincristine (BOLD) in metastatic melanoma. Cancer (1980) 46(11):2346-2348.
44. YORK RM, FOLTZ AT: Bleomycin, vincristine, lomustine, and DTIC chemotherapy for metastatic melanoma. Cancer (1988) 61(11):2183-2186.
45. THE PRUDENTE FOUNDATION MELANOMA STUDY GROUP: Chemotherapy of disseminated melanoma with bleomycin, vincristine, CCNU, and DTIC (BOLD regimen). Cancer (1989) 63(9):1676-1680.
46. PUNT CJ, VAN HERPEN CM, JANSEN RL, VREUGDENHIL G, MULLER EW, DE MULDER PH: Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD) plus interferon alpha for metastatic melanoma: a multicentre Phase II study. Br. J. Cancer (1997) 76(2):266-9.
47. PYRHONEN S, HAHKA-KEMPPINEN M, MUHONEN T et al.: Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD), and human leukocyte interferon for metastatic uveal melanoma. Cancer (2002) 95(11):2366-2372.
48. COSTANZI JJ, FLETCHER WS, BALCERZAK SP et al.: Combination chemotherapy plus levamisole in the treatment of disseminated malignant melanoma. A Southwest Oncology Group study. Cancer (1984) 53(4):833-836.
49. NATIONAL CANCER INSTITUTE OF CANADA MELANOMA GROUP: Vinblastine, bleomycin, and cis-platinum for the treatment of metastatic malignant melanoma. J. Clin. Oncol. (1984) 2(2):131-134.
50. LUIKART SD, KENNEALEY GT, KIRKWOOD JM: Randomized Phase III trial of vinblastine, bleomycin, and cisdichlorodiammine-platimun versus dacarbazine in malignant melanoma. J. Clin. Oncol. (1984) 2(3):164-168.